阿里健康首发兴齐眼药0.02%与0.04%新浓度阿托品滴眼液

中国网
Feb 24

2月24日,沈阳兴齐眼药自主研发的0.02%与0.04%浓度硫酸阿托品滴眼液正式在阿里健康首发。该产品适用于6至12岁、球镜度数为-1.00D至-4.00D(散光≤1.50D、屈光参差≤1.50D)的儿童,用于延缓近视进展。至此,兴齐眼药已形成0.01%、0.02%和0.04%三档浓度梯度,构建起国内首个用于儿童近视管理的低浓度阿托品阶梯式治疗体系,标志着我国儿童青少年近视药物干预迈入“因人施治、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10